04 August 2020

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

UK and US Patents Granted for LiquiBand^® Exceed

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced wound care specialist company, today announces that it has been granted UK and US patents for the LiquiBand^® Exceed range, providing protection until 2034.

The design of the applicator, tip and the raw materials used to manufacture the device has allowed it to be distinguished as a novel, patentable technology. These patents provide long-term protection on a core growth driver for the global LiquiBand^® portfolio, covering 30-35% of the current product range.

In addition, the UK patent will provide an additional tax benefit to the Group via the UK patent box scheme that is expected to reduce the effective tax rate for the Group by between 1% and 2% throughout the patent life.

Chris Meredith, Chief Executive Officer of AMS, commented: “With end sales demand for LiquiBand^® in the US showing early signs of recovery demonstrated by market share gains in the first quarter of 2020, these newly granted patents will further strengthen and protect growth in our core markets. They also highlight AMS’s continued ability to design, develop and sell innovative, patentable technology.”

– End –

For further information, please contact:

About Advanced Medical Solutions Group plc 

AMS is a world-leading developer and manufacturer of innovative and technologically advanced products for the global surgical and woundcare markets, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, and internal fixation devices, which it markets under its brands LiquiBand^®, RESORBA^®, and LiquiBandFix8^®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal^® brand as well as under white label. In 2019, the Group made two acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; and Biomatlante, an established developer and manufacturer of innovative surgical biomaterial technologies based in France.

AMS’s products, manufactured in the UK, Germany, France, the Netherlands, and the Czech Republic, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has approximately 700 employees. For more information, please see www.admedsol.com.